Saturday, 12 October 2013

Risk of early death from smoking more severe than thought, Australian study reveals


The risk of premature death from smoking is much more severe than previously thought for both light and heavy smokers, a large Australian study has revealed.
The study found that two thirds of deaths in current smokers can be attributed to tobacco use.
Professor Emily Banks from the Australian National University led the study, which followed 200,000 people over four years.
"The international rule of thumb is that half of all smoker deaths are directly caused by tobacco," she said.
"We found that [over the four years] people who are current smokers were three times more likely to die than people who had never smoked, and their life expectancy within that four-year period was diminished by 10 years compared to the never-smokers."

Key points:

  • Study followed 200,000 people over four years
  • Two thirds of deaths in current smokers can be attributed to tobacco use
  • Smoking reduces life expectancy by 10 years
  • Light smokers also face double risk of early death
Professor Banks is also the scientific director of the Sax Institute's 45 and Up study, which collected the data on the health of 10 per cent of New South Wales residents.
International research has long confirmed the connection between tobacco smoking and premature death from heart problems and lung cancer.
Tobacco smoking is estimated to be responsible for 9.7 per cent of the total disease burden, but until now large-scale Australian data has not been available.
Professor Banks says the effect that smoking has on the population depends on the intensity of smoking and how long people have been smoking.
"So in a way we need our data for our epidemic, and this is the first time that we have had data from the Australian population," she said.
She says the death rate matches patterns in the Britain and the United States.
"When people have been smoking for decades having started smoking in their late teens, and actually smoking heavily ... it's the pattern you see with a mature epidemic," she said

News also bad for 'light' smokers

Similarly, the news is not good for people who think of themselves as light smokers.
"The risk associated with smoking 10 cigarettes a day are similar to the risks of death associated with being morbidly obese, so with having a body mass index of 35 or more," Professor Banks said
"Most light smokers wouldn't think of themselves as having a risk that is similar to someone who is morbidly obese." 
While the study did find it is better to be a light smoker than a heavy smoker, it did confirm that giving up improves health.
"On average smokers reduce their life expectancy by 10 years," Professor Banks said.
"Quitting at any age reduces the risks and the earlier, the younger you quit the better."
People who had cancer and heart disease were eliminated at the start and there were adjustments for alcohol, socio-economic factors, weight and age.
The preliminary data is to be presented to the 10th annual 45 and Up Collaborators meeting in Sydney on Friday
Professor Banks says the next step in the research is the basic building block to apply to the general Australian population to find more exactly how many deaths can be attributed to smoking.
By Nonee Walsh via www.abc.net.au

Friday, 11 October 2013

Iowa grants gun permits to the blind



Iowa is granting permits to acquire or carry guns in public to people who are legally or completely blind.
No one questions the legality of the permits. State law does not allow sheriffs to deny an Iowan the right to carry a weapon based on physical ability.
The quandary centers squarely on public safety. Advocates for the disabled and Iowa law enforcement officers disagree over whether it's a good idea for visually disabled Iowans to have weapons.
On one side: People such as Cedar County Sheriff Warren Wethington, who demonstrated for The Des Moines Register how blind people can be taught to shoot guns. And Jane Hudson, executive director of Disability Rights Iowa, who says blocking visually impaired people from the right to obtain weapon permits would violate the Americans with Disabilities Act. That federal law generally prohibits different treatment based on disabilities
On the other side: People such as Dubuque County Sheriff Don Vrotsos, who said he wouldn't issue a permit to someone who is blind. And Patrick Clancy, superintendent of the Iowa Braille and Sight Saving School, who says guns may be a rare exception to his philosophy that blind people can participate fully in life.
Private gun ownership — even hunting — by visually impaired Iowans is nothing new. But the practice of visually impaired residents legally carrying firearms in public became widely possible thanks to gun permit changes that took effect in Iowa in 2011.
"It seems a little strange, but the way the law reads we can't deny them (a permit) just based on that one thing," said Sgt. Jana Abens, a spokeswoman for the Polk County Sheriff's Department, referring to a visual disability.
Polk County officials say they've issued weapons permits to at least three people who can't legally drive and were unable to read the application forms or had difficulty doing so because of visual impairments.
And sheriffs in three other counties — Jasper, Kossuth and Delaware — say they have granted permits to residents who they believe have severe visual impairments.
"I'm not an expert in vision," Delaware County Sheriff John LeClere said. "At what point do vision problems have a detrimental effect to fire a firearm? If you see nothing but a blurry mass in front of you, then I would say you probably shouldn't be shooting something."
Training the visually impaired
In one Iowa county, blind residents who want weapons would likely receive special training.
Wethington, the Cedar County sheriff, has a legally blind daughter who plans to obtain a permit to carry when she turns 21 in about two years. He demonstrated for the Register how he would train blind people who want to carry a gun.
"If sheriffs spent more time trying to keep guns out of criminals' hands and not people with disabilities, their time would be more productive," Wethington said as he and his daughter took turns practice shooting with a semi-automatic handgun on private property in rural Cedar County.
The number of visually impaired or blind Iowans who can legally carry weapons in public is unknown because that information is not collected by the state or county sheriffs who issue the permits.
Clancy, superintendent of the Iowa Braille and Sight Saving School, said the range of sight among people who are classified as legally blind varies greatly. He believes there are situations where such applicants can safely handle a gun.
However, he also expressed concerns.
"Although people who are blind can participate fully in nearly all life's experiences, there are some things like the operation of a weapon that may very well be an exception," Clancy said.
The Gun Control Act of 1968 and other federal laws do not prohibit blind people from owning guns. But unlike Iowa, some states have laws that spell out whether visually impaired people can obtain weapon permits.
Vision requirements are either directly or indirectly part of the weapon permit criteria in some surrounding states.
In Nebraska, for example, applicants for a permit to carry a concealed handgun must provide "proof of vision" by either presenting a valid state driver's license or a statement by an eye doctor that the person meets vision requirements set for a typical vehicle operator's license.
Other states have indirect requirements that could — but don't automatically — disqualify people who are blind. That includes Missouri and Minnesota, where applicants must complete a live fire test, which means they have to shoot and hit a target.
A 50-state database of gun permit requirements published by USACarry.com also shows that South Carolina has a law that requires proof of vision before a person is approved for a weapons permit.
Wisconsin, like Iowa, has no visual restrictions on gun permit applicants. Illinois lawmakers enacted a concealed weapons law in July but permits have not yet been issued. Illinois' qualifications don't specifically require a visual test, but applicants must complete firearms training that includes range instruction.
The National Federation of the Blind does not track states that require vision tests as part of weapon permit processes and has not taken an official stand on the issue. But its members are generally opposed to such laws, said Chris Danielsen, director of public relations for the group.
"There's no reason solely on the (basis) of blindness that a blind person shouldn't be allowed to carry a weapon," Danielsen said. "Presumably they're going to have enough sense not to use a weapon in a situation where they would endanger other people, just like we would expect other people to have that common sense."
Iowa requires training for anyone who is issued a permit to carry a weapon in public, but that requirement can be satisfied through an online course that does not include any hands-on instruction or a shooting test.
A provision in Iowa's law allows sheriffs to deny a permit if probable cause exists to believe that the person is likely to use the weapon in such a way that it would endanger themselves or others. Many sheriffs noted, however, that the provision relates to specific documented actions, and applicants who appealed their cases would likely win.
Hudson, executive director of Disability Rights Iowa, believes changing the state law to deny blind people or others with physical disabilities the right to carry arms would violate federal disabilities law.
Part of the Americans with Disabilities Act requires a public entity to conduct an individualized analysis to make a reasonable judgment before denying a service. Hudson believes someone could successfully challenge Nebraska's proof of vision requirement as illegal.
"The fact that you can't drive a car doesn't mean you can't go to a shooting range and see a target," Hudson said.

Aircraft noise linked to higher rate of cardiovascular disease, according to airport studies


Two international studies have found that aircraft noise may be leading to a rise in heart and lung disease.
Scientists say noise levels could be linked to more stress, sleep deprivation and high blood pressure in people - findings that could have implications for new airports slated for residential areas in Australia.
Professor Paul Elliott from Imperial College London worked on one study that investigated millions of people living near Heathrow.
He found that people living around the major international airport had a 3.5 per cent higher rate of hospital admissions for cardiovascular disease.
The results were vetted for other factors that could affect the data, including sex, ethnicity and smoking.
The boroughs experience noise levels at least 10 decibels higher than the average loud noise, which sits around 70 decibels.
"We know that acute exposure to loud noises can affect a startled reaction in the person with an increase in heart rate and a short-term increase in blood pressure," he said.
"And there is some evidence that this rise in blood pressure may be sustained if there's continual exposure to louder noises."
A vacuum cleaner is about 70 decibels, a lawnmower is about 90 decibels and a jet engine taking off is more than 100 decibels.
Another similar study, conducted by academics at the Boston University School of Public Health and Harvard School of Public Health, looked at six million people aged 65 or more, living around major airports in the United States.
Professor Jon Levy says his results are consistent with the UK findings, with a 2.3 per cent higher rate of hospital admissions.
"The health effects of noise should be thought about and taken into account when looking at airports and airport sitting or expansion," he said.

Strategies to reduce the impact of noise

In the United States, the noise study is being analysed by the US Federal Aviation Authority, which partly funded the research.
Professor Levy says there needs to be a focus on strategies that reduce aircraft noise exposure, including the soundproofing of homes, modified flight paths, and quieter aircraft.
But anti-aircraft noise groups say those measures are just band-aid solutions.
No Aircraft Noise Party spokesman Allan Rees wants a second Sydney airport to relieve the pressure on Kingsford Smith.
"Firstly on the double glazing: this is Sydney," he said.
"This is a mild, moderate climate. We want to have the windows open. We don't want to live in air-conditioned concrete boxes. It's not good living conditions and there's all the outdoor activity that gets interrupted as well.
"As far as the quieter aircraft, as I say, the newer aircraft are quieter, [but] not a great deal. They're still very noisy but that's outweighed by the increase in the number of aircraft and the fact that the average size of the aircraft operating at Mascot is going up steadily."
The Federal Government has not committed to building a second Sydney airport, and the New South Wales Government says capacity at the current site can be safely increased.
Both studies were published in the latest British Medical Journal.
The world Today by Eliza Harvey

Thursday, 10 October 2013

Centipede venom may fight chronic pain

The venom used by a centipede to paralyse prey contains a molecule that new research shows is more effective than morphine in blocking pain.
The finding in mice models could lead to the development of drugs for people with ongoing chronic pain, says co-author of the study Professor Glenn King, of the University of Queensland.
The current study targets human proteins known as voltage-gated sodium channels (Nav) that play a critical role in electrical signalling in neurons and other excitable cells.
King, a research fellow at the Institute for Molecular Bioscience, says humans have nine different Nav channels, with earlier studies showing the Nav1.7 channel plays a key role in pain transmission.
He says people with a mutation of this protein are unable to experience pain.
Previous research to target this channel has been hindered because of the impact of drug candidates on other Nav channels, which among other things play important roles in heart and muscle function.
"The difficulty is finding molecules that are selective for this one [Nav1.7] channel," he says.
In a study published this week in the Proceedings of the National Academy of Sciences, King and his Chinese colleagues show venom from the Chinese redheaded centipede (Scolopendra subspinipes mutilans) has 150 times selectivity for Nav1.7 over other Nav channels.
King says mice were injected with a peptide from the venom - Ssm6a - at a high dose and suffered no side effects with no impact on blood pressure or heart rate.
In thermal and acid-induced pain tests, the effect of the molecule "was similar to morphine", while in chemical-induced pain experiments it was more potent than morphine.
King says it is unlikely humans will develop a tolerance or addiction to drugs based on the venom molecule because unlike morphine it is not used to block receptors.
The work builds on an increasing body of research focusing on animal venoms for use in pain relief, but this is the first study to look at centipedes.
The current study focuses on a centipede that is farmed in China for consumption, but King and his colleagues believe the findings suggest centipede venom - which has been overlooked to date - may provide a source of lead molecules for drug development.
King agrees it is counterintuitive that a molecule used for predation could have therapeutic use.
However he says the key difference in ion channels between insects and humans makes this possible.
In contrast to humans, insects have only a single Nav channel, which is a common target of peptides in the venom of other arthropod predators such as scorpions and spiders.
"Centipedes worked out hundreds of millions of years ago the easiest way to catch prey was to paralyse them by blocking their Nav channel," King says.
"We're just lucky that of the nine Nav channels in humans, it hit the one we were after."
Recent US studies have shown the economic cost of chronic pain to be about $600 billion annually - more than the combined annual cost of cancer, heart disease and diabetes.
King says it is estimated at any one time about 20 per cent of the population on average is suffering from chronic pain, defined as pain that persists for three months or more.
He says the next step in their research is to trial the peptide using more sophisticated pain models that replicate pain associated with conditions such as rheumatoid arthritis and cancer.
The finding in mice models could lead to the development of drugs for people with ongoing chronic pain, says co-author of the study Professor Glenn King, of the University of Queensland.
The current study targets human proteins known as voltage-gated sodium channels (Nav) that play a critical role in electrical signalling in neurons and other excitable cells.
King, a research fellow at the Institute for Molecular Bioscience, says humans have nine different Nav channels, with earlier studies showing the Nav1.7 channel plays a key role in pain transmission.
He says people with a mutation of this protein are unable to experience pain.
Previous research to target this channel has been hindered because of the impact of drug candidates on other Nav channels, which among other things play important roles in heart and muscle function.
"The difficulty is finding molecules that are selective for this one [Nav1.7] channel," he says.
In a study published this week in the Proceedings of the National Academy of Sciences, King and his Chinese colleagues show venom from the Chinese redheaded centipede (Scolopendra subspinipes mutilans) has 150 times selectivity for Nav1.7 over other Nav channels.
King says mice were injected with a peptide from the venom - Ssm6a - at a high dose and suffered no side effects with no impact on blood pressure or heart rate.
In thermal and acid-induced pain tests, the effect of the molecule "was similar to morphine", while in chemical-induced pain experiments it was more potent than morphine.
King says it is unlikely humans will develop a tolerance or addiction to drugs based on the venom molecule because unlike morphine it is not used to block receptors.
The work builds on an increasing body of research focusing on animal venoms for use in pain relief, but this is the first study to look at centipedes.
The current study focuses on a centipede that is farmed in China for consumption, but King and his colleagues believe the findings suggest centipede venom - which has been overlooked to date - may provide a source of lead molecules for drug development.
King agrees it is counterintuitive that a molecule used for predation could have therapeutic use.
However he says the key difference in ion channels between insects and humans makes this possible.
In contrast to humans, insects have only a single Nav channel, which is a common target of peptides in the venom of other arthropod predators such as scorpions and spiders.
"Centipedes worked out hundreds of millions of years ago the easiest way to catch prey was to paralyse them by blocking their Nav channel," King says.
"We're just lucky that of the nine Nav channels in humans, it hit the one we were after."
Recent US studies have shown the economic cost of chronic pain to be about $600 billion annually - more than the combined annual cost of cancer, heart disease and diabetes.
King says it is estimated at any one time about 20 per cent of the population on average is suffering from chronic pain, defined as pain that persists for three months or more.
He says the next step in their research is to trial the peptide using more sophisticated pain models that replicate pain associated with conditions such as rheumatoid arthritis and cancer.
The finding in mice models could lead to the development of drugs for people with ongoing chronic pain, says co-author of the study Professor Glenn King, of the University of Queensland.
The current study targets human proteins known as voltage-gated sodium channels (Nav) that play a critical role in electrical signalling in neurons and other excitable cells.
King, a research fellow at the Institute for Molecular Bioscience, says humans have nine different Nav channels, with earlier studies showing the Nav1.7 channel plays a key role in pain transmission.
He says people with a mutation of this protein are unable to experience pain.
Previous research to target this channel has been hindered because of the impact of drug candidates on other Nav channels, which among other things play important roles in heart and muscle function.
"The difficulty is finding molecules that are selective for this one [Nav1.7] channel," he says.
In a study published this week in the Proceedings of the National Academy of Sciences, King and his Chinese colleagues show venom from the Chinese redheaded centipede (Scolopendra subspinipes mutilans) has 150 times selectivity for Nav1.7 over other Nav channels.
King says mice were injected with a peptide from the venom - Ssm6a - at a high dose and suffered no side effects with no impact on blood pressure or heart rate.
In thermal and acid-induced pain tests, the effect of the molecule "was similar to morphine", while in chemical-induced pain experiments it was more potent than morphine.
King says it is unlikely humans will develop a tolerance or addiction to drugs based on the venom molecule because unlike morphine it is not used to block receptors.
The work builds on an increasing body of research focusing on animal venoms for use in pain relief, but this is the first study to look at centipedes.
The current study focuses on a centipede that is farmed in China for consumption, but King and his colleagues believe the findings suggest centipede venom - which has been overlooked to date - may provide a source of lead molecules for drug development.
King agrees it is counterintuitive that a molecule used for predation could have therapeutic use.
However he says the key difference in ion channels between insects and humans makes this possible.
In contrast to humans, insects have only a single Nav channel, which is a common target of peptides in the venom of other arthropod predators such as scorpions and spiders.
"Centipedes worked out hundreds of millions of years ago the easiest way to catch prey was to paralyse them by blocking their Nav channel," King says.
"We're just lucky that of the nine Nav channels in humans, it hit the one we were after."
Recent US studies have shown the economic cost of chronic pain to be about $600 billion annually - more than the combined annual cost of cancer, heart disease and diabetes.
King says it is estimated at any one time about 20 per cent of the population on average is suffering from chronic pain, defined as pain that persists for three months or more.
He says the next step in their research is to trial the peptide using more sophisticated pain models that replicate pain associated with conditions such as rheumatoid arthritis and cancer.
Via http://www.abc.net.au

Wednesday, 9 October 2013

LATEST SCIENTIFIC DISCOVERIES: 'Designer baby' patent raises ethical questions

LATEST SCIENTIFIC DISCOVERIES: 'Designer baby' patent raises ethical questions: 23forMe says the patent was for a calculator that offered a ways for parents to see what kind of traits such as eye colour the child migh...

'Designer baby' patent raises ethical questions

23forMe says the patent was for a calculator that offered a ways for parents to see what kind of traits such as eye colour the child might inherit(Source: loops7/iStockphoto)

Bioethicists have raised the red flag over an American patent for a method that could allow people to choose genetic traits like eye colour in children sired from donor eggs or sperm.
The patent for what is called a "gamete (egg or sperm) donor selection" method, was granted by the US Patent and Trademark Office (USPTO) to the firm 23andMe on 24 September.
A description on the USPTO website said the "technique allows the potential gamete recipients to make more informed donor choices".
"What 23andMe is claiming is a method by which prospective donors of ova and/or sperm may be selected so as to increase the likelihood of producing a human baby with characteristics desired by the prospective parents," write medical ethicists from Belgium, the Netherlands and France in the journal Genetics in Medicine.
This would be based on a computerised comparison of the genomic data of the egg provider with that of the sperm provider.
Characteristics on the parents' "shopping list" could include height, eye colour, muscle development, personality traits, or risk of developing certain types of cancer and other diseases, say the commentators.
A figure attached to the patent application would allow prospective parents to indicate whether "I prefer a child with": "longest expected life span", "least expected life cost of health care", or "least expected cumulative duration of hospitalisation", they say.
There were also options for "0 per cent likely endurance athlete" and "100 per cent likely sprinter", though the company had stated it could not guarantee the outcome but merely boost the chances of a child having the desired traits.
The commentators describe the method as "hugely ethically controversial" -- particularly as it allows for the selection of characteristics that have nothing to do with the child's health.
"At no stage during the examination of the patent application did the patent office examiner question whether techniques for facilitating the 'design' of future human babies were appropriate subject matter for a patent," they write.

Crossing the line

Associate Professor Jayne Lucke from the Centre for Clinical Research at the University of Queensland says the patent granted to 23forMe appears to cross the line between the accepted practice of preimplantation genetic diagnosis to eliminate a specific disease risk and the controversial idea of selecting socially desirable traits.
"By framing the proposal around the method, the patent has been granted without appearing to address the moral and ethical implications, or the question about whether the procedure is appropriate," says Lucke.
She says the commentary in Genetics in Medicine raises a number of questions for public debate surrounding the use of genetic and reproductive technologies.
"The idea of a "baby farm" manufacturing babies on demand for customers with no emotional or biological connection to the gametes or the resulting child is clearly unacceptable. But where should we draw the line between methods for disease prevention and those seeking to enhance future children with the "right" characteristics, whatever they may be?" she asks.
Medical ethicist Dr Leslie Cannold says patent law was never intended to manage the moral complexities that arise from 23and Me's screen.
"It is up to society to get our collective heads around what is happening in the the lab, and to deploy the political process to regulate it accordingly, says Cannold, who holds an adjunct position at Monash University.
"While it is questionable whether science can deliver many of the genetic predispositions promised in the 23andMe patent, what is certain is that the science that forms the foundation of the application was never intended for such frivolous use."

Broad definitions

23forMe says the patent, applied for more than five years ago, was for a tool dubbed Family Traits Inheritance Calculator that offered "an engaging way for you and your partner to see what kind of traits your child might inherit from you" -- from eye colour to whether the child will be able to perceive bitter taste or be lactose intolerant.
The language of the patent was much broader than the technology to support the calculator, the company says in a blog on its website.
"At the time 23andMe filed the patent, there was consideration that the technology could have potential applications for fertility clinics, so language specific to the fertility treatment process was included," it says.
"The company never pursued the concepts discussed in the patent beyond our Family Traits Inheritance Calculator, nor do we have any plans to do so."
Via www.abc.net.au


Red Wine Chemical Could Let You Live to 150 years



A number of studies have pointed out the health benefits of resveratrol, a compound found naturally in red wine and other foods like berries and peanuts. Now scientists are testing synthetic forms of resveratrol on patients with an eye toward extending life.
Like calorie restriction and exercise — but without weight loss — resveratrol speeds up a target enzyme called SIRT1, which has the potential to prevent disease and slow aging. The latest findings were recently reported in the journal Science.
“Some of us could live to 150,” Harvard genetics professor David Sinclair told the Daily Mail. “But we won’t get there without more research.”
The drugs that were tested are 100 times stronger than what you’d find in a glass of wine. They could be oral or topical and may be available within five years. via the Daily Mail
Image: iStockphoto

Tuesday, 8 October 2013

Artificial DNA Brings Us Closer Than Ever to Synthesizing Entirely New Forms of Life


New research has brought us closer than ever to synthesizing entirely new forms of life. An international team of researchers has shown that artificial nucleic acids - called "XNAs" - can replicate and evolve, just like DNA and RNA.
We spoke to one of the researchers who made this breakthrough, to find out how it can affect everything from genetic research to the search for alien life.
The researchers, led by Philipp Holliger and Vitor Pinheiro, synthetic biologists at the Medical Research Council Laboratory of Molecular Biology in Cambridge, UK, say their findings have major implications in everything from biotherapeutics, to exobiology, to research into the origins of genetic information itself. This represents a huge breakthrough in the field of synthetic biology.

The "X" Stands for "Xeno"

Every organism on Earth relies on the same genetic building blocks: the the information carried in DNA. But there is another class of genetic building block called "XNA" — a synthetic polymer that can carry the same information as DNA, but with a different assemblage of molecules.
The "X" in XNA stands for "xeno." Scientists use the xeno prefix to indicate that one of the ingredients typically found in the building blocks that make up RNA and DNA has been replaced by something different from what we find in nature — something "alien," if you will.
XNA is synthetic DNA that's stronger than the real thingSEXPAND
Strands of DNA and RNA are formed by stringing together long chains of molecules called nucleotides. A nucleotide is made up of three chemical components: a phosphate (labeled here in red), a five-carbon sugar group (labeled here in yellow, this can be either a deoxyribose sugar — which gives us the "D" in DNA — or a ribose sugar — hence the "R" in RNA), and one of five standard bases (adenine, guanine, cytosine, thymine or uracil, labeled in blue).
XNA is synthetic DNA that's stronger than the real thingSEXPAND
The molecules that piece together to form the six XNAs investigated by Pinheiro and his colleagues (pictured here) are almost identical to those of DNA and RNA, with one exception: in XNA nucleotides, thedeoxyribose and ribose sugar groups of DNA and RNA (corresponding to the middle nucleotide component, labeled yellow in the diagram above) have been replaced. Some of these replacement molecules contain four carbons atoms instead of the standard five. Others cram in as many as seven carbons. FANA (pictured top right) even contains a fluorine atom. These substitutions make XNAs functionally and structurally analogous to DNA and RNA, but they also make them alien, unnatural, artificial.

Information Storage vs Evolution

But scientists have been synthesizing XNA molecules for well over a decade. What makes the findings of Pinheiro and his colleagues so compelling isn't the XNA molecules themselves, it's what they've shown these alien molecules are capable of, namely: replication and evolution.
"Any polymer can store information," Pinheiro tells io9. What makes DNA and RNA unique, he says, "is that the information encoded in them [in the form of genes, for example] can be accessed and copied." Information that can be copied from one genetic polymer to another can be propagated; and genetic information that can be propagated is the basis for heredity — the passage of traits from parent to offspring.
XNA is synthetic DNA that's stronger than the real thingSEXPAND
In DNA and RNA, replication is facilitated by molecules called polymerases. Using a crafty genetic engineering technique called compartmentalized self-tagging (or "CST"), Pinheiro's team designed special polymerases that could not only synthesize XNA from a DNA template, but actually copy XNA backinto DNA. The result was a genetic system that allowed for the replication and propagation of genetic information.
A simplified analogy reveals the strengths and weaknesses of this novel genetic system: You can think of a DNA strand like a classmate's lecture notes. DNA polymerase is the pen that lets you copy these notes directly to a new sheet of paper. But let's say your friend's notes are written in the "language" of XNA. Ideally, your XNA-based genetic system would have a pen that could copy these notes directly to a new sheet of paper. What Pinheiro's team did was create two distinct classes of writing utensil — one pen that copies your friend's XNA-notes into DNA-notes, and a second pen that converts those DNA notes back into XNA-notes.
Is it the most efficient method of replication? No. But it gets the job done. What's more, it does all this copying to and from DNA with a high degree of accuracy (after all, what good is replication if the copy looks nothing like the original?). The researchers achieved a replication fidelity ranging from 95% in LNA to as high as 99.6% in CeNA — the kind of accuracy Pinheiro says is essential for evolution:
"The potential for evolution is closely tied with how much information is being replicated and the error in that process," he explains. "The more error-prone… a genetic system is, the less information can be feasibly evolved." A genetic system as accurate as theirs, on the other hand, should be capable of evolution.
XNA is synthetic DNA that's stronger than the real thingSEXPAND
The researchers put this claim to the test by showing that XNA strands made up of the HNA xeno-nucleotides like the one pictured here could evolve into specific sequences capable of binding target molecules (like an RNA molecule, or a protein) tightly and specifically. Researchers call this guided evolution, and they've been doing it with natural DNA for some time. The fact that it can also be accomplished in the lab with synthetic DNA indicates that such a system could, in theory, work in a living organism.
"The HNA system we've developed," explains Pinheiro, is "robust enough for meaningful information to be stored, replicated and evolved."
The researchers' findings are published in today's issue of Science.
Top image via Shutterstock; XNA moieties via Science; all other images via Wikimedia Commons

First Artificial Pancreas Approved to Treat Diabetes

Diabetes has reached epidemic proportions in the United States and many other countries around the world. And unlike the more common acquired form of diabetes, the Type 1 form of the illness has neither prevention nor cure. Sufferers simply don’t produce insulin, the hormone excreted by the pancreas to process glucose in the body. Patients are stuck monitoring their blood sugar levels with pinpricks and injecting themselves with synthetic insulin.
The Food and Drug Administration recently issued its first-ever approval of an artificial pancreas that may make life easier and healthier for such patients. The device, made by Minneapolis-based Medtronics, relies on a computer algorithm to sync the results of a continuous reading of the wearer’s glucose levels with a pump that provides appropriate amounts of insulin.
Diabetics can currently get continuous glucose monitoring devices and insulin pumps, but the two are not connected.
“This is a significant step towards an artificial pancreas device system,” FDA press officer Jenny Haliski told Singularity Hub.
Although the Medtronics device is called an artificial pancreas, it looks more like pager, which hooks over to the belt and attaches to a sensor that patients insert under the skin.
Its advantage is that it can automatically shut off the supply of insulin if the wearer’s glucose levels fall too low, which can lead to a diabetic coma. The device first alerts the wearer if blood sugar becomes dangerously low, but if s/he doesn’t respond, it shuts off the insulin supply for two hours. The sensor is also billed as more accurate, though still not as accurate as one might hope: Its false alarm rate is 33 percent, according to Medtronics.
Still, the connected monitor and pump setup has been some time in the making and may be the best way to treat diabetes in the absence of a  breakthrough.
For patients it offers real improvements in quality of life.
“Wow, this is amazing. It says a couple of weeks from now it will be available. Wow! This is huge. No competitor is anywhere near this,” said Ami Eaton, a San Franciscan in her 30s who suffers from Type 1 diabetes. She uses a Medtron insulin pump, which allows her to set how much insulin to provide based on manual blood sugar readings.
Eaton explained that, for fear of passing out, she sometimes gives herself only a conservative amount of insulin, which at times leaves her blood sugar levels higher than her doctor would like.
Medtronic says it will begin selling the device, called the MiniMed 530G, in the next few weeks.
The company hopes its next model will be a “fully automated artificial pancreas” that requires almost no input from the wearer.
Images: Medtronic MiniMed courtesy Medtronic; chart via FDA, report via singularityhub.com